Literature DB >> 14519088

Progesterone antagonists and progesterone receptor modulators.

Irving M Spitz1.   

Abstract

Since the discovery of the antiprogestin RU 486 (mifepristone), other compounds have been synthesised that function as pure progesterone antagonists or progesterone receptor modulators. The latter are mixed agonists-antagonists. Mifepristone is usually used to terminate pregnancy but these compounds have numerous other applications in female healthcare. Mifepristone is an excellent agent for emergency contraception. Many progesterone antagonists and progesterone receptor modulators display antiproliferative effects on the endometrium and thus have application in the treatment of endometriosis and uterine myoma without being associated with hypoestrogenism and bone loss. They also have contraceptive potential by suppressing follicular development, blocking the luteinising hormone surge and retarding endometrial maturation. Finally, they have clinical application in GeneSwitch system, a plasmid-based method enabling controlled expression of specific genes (e.g., erythropoietin) using a progesterone antagonist as the inducer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519088     DOI: 10.1517/13543784.12.10.1693

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  3 in total

1.  Independent roles of beta-adrenergic and glucocorticoid receptors in systemic and pulmonary effects of ozone.

Authors:  Andres R Henriquez; Samantha J Snow; Mette C Schladweiler; Colette N Miller; Urmila P Kodavanti
Journal:  Inhal Toxicol       Date:  2020-05-04       Impact factor: 2.724

2.  Stochastic model of ERK-mediated progesterone receptor translocation, clustering and transcriptional activity.

Authors:  Tatiana T Marquez-Lago; Stanly Steinberg
Journal:  Sci Rep       Date:  2022-07-11       Impact factor: 4.996

3.  Exploring Flexibility of Progesterone Receptor Ligand Binding Domain Using Molecular Dynamics.

Authors:  Liangzhen Zheng; Valerie Chunling Lin; Yuguang Mu
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.